Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/4/2010

rresponding periods of 2009. The increases in 2010 were due mainly to higher employee expenses including severance charges, professional fees for legal and accounting services, employee recruitment costs and stock based compensation expense.

In September 2010, we revised our sublease income assumptions used to estimate the excess lease facility liability associated with our office space located in Bothell, Washington. This change in estimate resulted in an increase of the excess lease liability and $4.0 million in restructuring expense recorded in September 2010. This is a non-cash item and does not impact the Company's cash flow projections going forward. The estimated liability remaining with respect to excess facilities was $7.8 million as of September 30, 2010.

The net loss for the third quarter was $6.9 million compared to a $2.4 million net loss in the same period 2009. This increase is primarily due to the non-cash restructuring expense related to our facilities lease. For the nine months ended September 30, 2010 the net loss increased to $9.8 million from $9.4 million in 2009.

The Company had $42.1 million in cash and investment securities as of September 30, 2010, compared to $64.6 million at December 31, 2009. Together with the estimated $46.7 million net proceeds from the public offering completed in October 2010, we anticipate ending the year with cash, cash equivalents, short-term investments, and amounts receivable of between $83 million and $85 million.

The Company had 9,658,591 shares outstanding as of November 4, 2010.  Conference Call Today at 4:30 p.m. ET 
OncoGenex management will host a conference call at 4:30 p.m. Eastern Time today to provide a business update and discuss the third quarter results. A live webcast will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at www.ir.o
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
2. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
3. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
4. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
5. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
7. OncoGenex Reports Second Quarter Financial Results
8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
10. OncoGenex Reports First Quarter Financial Results
11. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Efficient Cellular Fractionation for RNA , ... Ambion's Protein and RNA Isolation System, , ... total RNA and native protein from the same ... tissues that are either fresh, , ...
... Because of its apparent specificity, , ... accelerating the functional characterization of , ... and basic research efforts. To ensure ... data, however, proper experimental design and controls are , ...
... mir ... Sensitive -- Detect miRNA or siRNA in as little as 10 ng ... need to optimize hybridization , or washing conditions , ... to membrane for hybridization , ...
Cached Biology Technology:Efficient Cellular Fractionation for RNA , and Protein Isolation 2Efficient Cellular Fractionation for RNA , and Protein Isolation 3Efficient Cellular Fractionation for RNA , and Protein Isolation 4Efficient Cellular Fractionation for RNA , and Protein Isolation 5Efficient Cellular Fractionation for RNA , and Protein Isolation 6Efficient Cellular Fractionation for RNA , and Protein Isolation 7Designing Controls for siRNA , Experiments 2Designing Controls for siRNA , Experiments 3Designing Controls for siRNA , Experiments 4Designing Controls for siRNA , Experiments 5Detecting Attomole Amounts of Small RNA 2Detecting Attomole Amounts of Small RNA 3
(Date:4/17/2014)... 16, 2014. Kessler Foundation has been named awardee ... the Department of Defense Spinal Cord Injury Research ... for the randomized, double-blinded, controlled, multi-site clinical trial, ... muscle strength after spinal cord injury. Dr. Forrest ... Research at Kessler Foundation. Two additional sites will ...
(Date:4/17/2014)... This news release is available in German . ... enable us to recognise objects; they also provide us with ... we run, turn around, fall or sit still in a ... characteristic motion trace on our retinas. Seemingly without effort, our ... can maintain a stable position and a steady gaze during ...
(Date:4/17/2014)... in German . ... money demanded of him, he can expect his premises to ... fear of the consequences is enough to make restaurant owners ... which lay their eggs in other birds, nests. If the ... take their revenge by destroying the entire nest. Consequently, it ...
Breaking Biology News(10 mins):Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... RICHMOND, Va. (April 19, 2010) Virginia Commonwealth University ... play a key role in the development of liver ... in more than 90 percent of patients with the ... at the Virginia Commonwealth University Massey Cancer Center and ...
... Chesapeake Biological Laboratory Director Dr. Margaret Palmer has been ... Science with its President,s Award for Excellence in Science ... about the environmental impacts of mountaintop mining. "Day ... the impact of her research beyond academia and into ...
... hard metals or semiconductors to soft organic or biological products. ... by Mother Nature. The applications in medicine and ... face of nanoscience at The Florida State University. ... a chip" that can diagnose illness? That and much more ...
Cached Biology News:Researchers identify new gene involved in the development of liver cancer 2UMCES ecologist Margaret Palmer recognized for promoting the role of science in public policy 2Bionanotechnology has new face, world-class future at Florida State 2Bionanotechnology has new face, world-class future at Florida State 3
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: